Nektar Therapeutics (NASDAQ:NKTR) Share Price Crosses Above Two Hundred Day Moving Average of $0.98

Nektar Therapeutics (NASDAQ:NKTR) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.98 and traded as high as $1.17. Nektar Therapeutics shares last traded at $1.16, with a volume of 2,574,335 shares trading hands.

Analyst Ratings Changes

A number of analysts recently commented on the company. Jefferies Financial Group raised their price target on Nektar Therapeutics from $0.50 to $1.00 and gave the stock a “hold” rating in a research note on Wednesday, March 6th. William Blair reaffirmed a “market perform” rating on shares of Nektar Therapeutics in a research report on Tuesday, March 5th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, Nektar Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $3.50.

Nektar Therapeutics Trading Up 6.4 %

The company has a market cap of $213.46 million, a PE ratio of -1.26 and a beta of 0.71. The stock has a 50 day moving average price of $1.46 and a 200 day moving average price of $0.98.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.03. Nektar Therapeutics had a negative return on equity of 107.31% and a negative net margin of 195.02%. The business had revenue of $21.64 million during the quarter, compared to analyst estimates of $14.91 million. During the same quarter last year, the firm posted ($0.25) earnings per share. Equities analysts expect that Nektar Therapeutics will post -0.84 EPS for the current fiscal year.

Insider Activity at Nektar Therapeutics

In other Nektar Therapeutics news, major shareholder Deep Track Capital, Lp sold 56,000 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $1.78, for a total transaction of $99,680.00. Following the completion of the transaction, the insider now owns 18,344,000 shares of the company’s stock, valued at $32,652,320. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Nektar Therapeutics news, major shareholder Deep Track Capital, Lp sold 56,000 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $1.78, for a total value of $99,680.00. Following the sale, the insider now directly owns 18,344,000 shares of the company’s stock, valued at $32,652,320. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Howard W. Robin sold 16,650 shares of the stock in a transaction on Friday, May 17th. The stock was sold at an average price of $1.75, for a total value of $29,137.50. Following the completion of the sale, the chief executive officer now directly owns 863,239 shares in the company, valued at $1,510,668.25. The disclosure for this sale can be found here. Insiders sold a total of 99,505 shares of company stock valued at $165,089 in the last three months. Company insiders own 3.71% of the company’s stock.

Institutional Trading of Nektar Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of NKTR. State Board of Administration of Florida Retirement System purchased a new stake in shares of Nektar Therapeutics during the first quarter valued at approximately $63,000. Mackenzie Financial Corp bought a new position in shares of Nektar Therapeutics in the 4th quarter worth approximately $42,000. Citigroup Inc. boosted its holdings in shares of Nektar Therapeutics by 1,993.9% in the third quarter. Citigroup Inc. now owns 77,978 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 74,254 shares during the last quarter. SG Americas Securities LLC grew its position in Nektar Therapeutics by 30.6% during the fourth quarter. SG Americas Securities LLC now owns 101,687 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 23,829 shares during the period. Finally, Marquette Asset Management LLC increased its holdings in Nektar Therapeutics by 25.5% during the fourth quarter. Marquette Asset Management LLC now owns 186,163 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 37,785 shares during the last quarter. 75.88% of the stock is currently owned by institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.